Spark loses another top exec in the wake of $4.3B takeover by Roche — report
Days after bidding farewell to co-founder Kathy High, Spark Therapeutics — now operating under Roche — has one more opening on its C-suite.
Kathy Reape, who joined the Philadelphia-based biotech in 2016 as head of clinical R&D and became chief medical officer in 2018, is reportedly set to leave.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.